ReviewInternational journal of molecular sciences2024
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis.International journal of dermatology · 2026Pooled it
- Effectiveness and Safety of Nemolizumab in Patients with Prurigo Nodularis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.Clinical reviews in allergy & immunology · 2025Pooled it
- Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials.American journal of clinical dermatology · 2026Trial
- Prurigo Nodularis in Two Siblings with Response to Oral Tofacitinib.Indian dermatology online journal · 2026Article
- Chronic prurigo in an adolescent patient successfully controlled with dupilumab.Skin health and disease · 2026Article
- Sex- and Gender-Related Differences in Pruritus in Dermatological Diseases: Insights into Inflammatory, Autoimmune, and Connective Tissue Disorders.Life (Basel, Switzerland) · 2026Review
- Standardizing Prurigo Control Assessment Globally: Linguistic Validation and Cross-cultural Adaptation of Prurigo Control Test in 18 Languages.Acta dermato-venereologica · 2026Article
- The State of the Art in Chronic Prurigo Nodularis.Dermatology and therapy · 2026Review
- Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel.Dermatology and therapy · 2026Review
- Adapting the Geriatric Medicine 5Ms Framework to Geriatric Dermatology.Drugs & aging · 2026Review
- Extensive skin ulcerations in an HIV-positive patient with AIDS: An atypical giant acquired perforating dermatosis-chronic prurigo spectrum presentation.JAAD case reports · 2026Article
- A Conceptual Disease Model of Symptoms and Impacts in Adults with Prurigo Nodularis: A Qualitative and Literature-Informed Study.Dermatology and therapy · 2026Article
- Transient Receptor Potential (TRP) Channels as Fundamental Regulators of Fibrosis and Pruritus-A New Therapeutic Target for Pathological Scar Management.International journal of molecular sciences · 2026Review
- Prurigo Nodularis and the Pain Cascade: Understanding the Pathogenesis and Approach to Management.The Journal of clinical and aesthetic dermatology · 2026Review
- Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents.Clinical, cosmetic and investigational dermatology · 2026Review
- Neuroimmune Interactions in Inflammatory Skin and Intestinal Diseases.Journal of inflammation research · 2026Review
- The Central Role of Th2 Immune Response in Inflammatory Dermatoses: From Pathogenesis to Targeted Therapies.International journal of molecular sciences · 2025Review
- New-onset Autoimmune Diseases in Patients with Prurigo Nodularis: A Global-federated Retrospective Cohort Study.Acta dermato-venereologica · 2025Article
- Serum SERPINB3/4 in Moderate-to-Severe Prurigo Nodularis: A Potential Biomarker for Disease Severity and Eosinophil-Related Parameters.Immunity, inflammation and disease · 2025Article
- Prurigo Nodularis in a Patient With Primary B-Cell Immunodeficiency Successfully Treated With Low-Dose Methotrexate: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pruritus that lasts for over 6 weeks can present in various forms, like papules, nodules, and plaque types, with prurigo nodularis (PN) being the most prevalent. The pathogenesis of PN involves the dysregulation of immune cell-neural circuits and is associated with peripheral neuropathies, possibly due to chronic scratching. PN is a persistent and challenging condition, involving complex interactions among the skin, immune system, and nervous system. Lesional skin in PN exhibits the infiltration of diverse immune cells like T cells, eosinophils, macrophages, and mast cells, leading to the release of inflammatory cytokines and itch-inducing substances. Activated sensory nerve fibers aggravate pruritus by releasing neurotransmitters, perpetuating a vicious cycle of itching and scratching. Traditional treatments often fail, but recent advancements in understanding the inflammatory and itch transmission mechanisms of PN have paved the way for innovative therapeutic approaches, which are explored in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.